Producer

Takeda Pharmaceutical Company (Plasma-Derived Therapeutics)

HQ JP · Tokyowebsite ↗

Takeda Pharmaceutical Company Limited (Tokyo Japan; TSE: 4502; NYSE: TAK; ~¥4.3T revenue; Japan's largest pharmaceutical company) is the world's #3 plasma fractionator through its Plasma-Derived Therapeutics (PDT) business division — the operations acquired from Baxter International's BioScience division in 2014 (BaxAlt / Baxalta acquisition completed 2016 for $32B). Takeda's PDT segment produces IVIG (GAMMAGARD LIQUID, HYQVIA), albumin, Factor VIII/IX/VWF products, and alpha-1 antitrypsin (GLASSIA) for immunodeficiency, hemophilia, hereditary angioedema, and respiratory disease patients globally. Takeda operates plasma collection centers under the BioLife Plasma Services brand in the US (300+ centers) and fractionation facilities in Lessines Belgium, Los Angeles CA, Covington GA, and Atlanta GA. Takeda's 2016 $32B acquisition of Shire (including Shire's Baxalta plasma business) was the largest acquisition in Japanese corporate history at the time.

1

Inputs supplied

1

Goods downstream

0

Facilities

0

Stories

What they make

1 input Takeda Pharmaceutical Company (Plasma-Derived Therapeutics) supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where it shows up

Goods downstream

Essential goods that depend on something Takeda Pharmaceutical Company (Plasma-Derived Therapeutics) makes, pick one to see the full supply chain.

What else they do

Business segments

The company's full revenue map, where this supply-chain role fits within their broader business.

  • Plasma-Derived Therapeutics (PDT)

    25%
  • Oncology

    20%
  • Rare Diseases

    18%
  • Gastroenterology (GI)

    17%
  • Neuroscience

    12%
  • Other

    8%

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

  • Did you know2024

    Takeda Pharmaceutical Company (Tokyo; TSE: 4502) is known in Japan as Japan's largest pharmaceutical company — primarily associated with cancer drugs (Velcade, Ninlaro), GI drugs (Entyvio), and CNS treatments. What the US donor plasma industry and European plasma therapy patients know is that the same Takeda operates BioLife Plasma Services — one of the largest US plasma collection businesses with 300+ donor centers where American donors are paid to donate plasma. The plasma collected from paid American donors in Midwestern BioLife centers is fractionated at Takeda's Belgian (Lessines) and US plants, and infused into European immunodeficiency and hemophilia patients as IVIG and Factor products. A Japanese pharmaceutical company runs the American plasma donor network that supplies life-critical protein therapies to European patients — a supply chain that depends on American donor willingness and Japanese manufacturing and distribution logistics. The US plasma donor who receives $50-100 per donation at a BioLife center may be unaware that the plasma bank is owned by Osaka's oldest pharmaceutical company.

    Takeda Pharmaceutical Company Limited
  • Origin2023

    Takeda Pharmaceutical was founded in 1781 in Osaka by Chobei Takeda — establishing a crude drug and traditional Japanese medicine shop during the late Edo period. For its first 150 years, Takeda sold traditional herbal medicines and, after the Meiji Restoration, began transitioning to Western pharmaceutical products. Takeda's $32B acquisition of Shire plc (Ireland/USA) in 2019 — the largest acquisition in Japanese corporate history at the time — included Shire's Baxalta (plasma-derived therapeutics from Baxter International) and brought Takeda 300+ US plasma collection centers under the BioLife Plasma Services brand. A 243-year-old Osaka traditional medicine shop is now the operator of the second-largest plasma collection network in the United States — collecting donor plasma from American paid donors and converting it into life-saving immunoglobulin and hemophilia therapies. The trajectory: Edo-period herbal medicine shop → modern Japanese pharma → $32B M&A → US plasma donor center operator.

    Takeda Pharmaceutical Company Limited